Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanosine-2',3'-O-methylidenephosphonate is a synthetic analog of guanosine, in which the 2' and 3' hydroxyl groups of the ribose moiety are protected as a methylidene acetal and the phosphate group is replaced by a phosphonate. This compound is structurally related to other guanosine derivatives such as guanosine-2',3'-O-ethylidenephosphonate, which has been studied as an experimental inhibitor of purine nucleoside phosphorylase. The methylidene modification may confer increased stability against enzymatic degradation compared to natural nucleotides or their simple esters. Its mechanism of action would be expected to involve interference with enzymes that process guanosine or its phosphorylated forms, potentially acting as an inhibitor or substrate mimic for nucleotide-processing enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanosine-2',3'-O-methylidenephosphonate.